Danish biotechnology company Zealand Pharma said on Thursday it had enrolled the first patient in a mid-stage trial with its weight-loss drug candidate petrelintide in people with overweight or ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

This came after Sun Pharma presented the BE study report along with revised clinical trial (CT) protocol no. ICR/23/013 ver.

Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

Amylin is a hormone that gives a feeling of fullness in the brain that suppresses appetite, reduces food intake, and delays gastric emptying. In a six-week, phase 1 study reported last year ...

In an hour-long meeting at Eli Lilly and Company’s headquarters in Indianapolis on April 15, the pharmaceutical company’s top ...

Amycretin is a dual receptor agonist that targets two key gut hormones, GLP-1 and amylin. Shares of Structure Therapeuticssoared 17.4% following LLY’s news. GPCR is conducting multiple mid-stage ...

The company is also working on combining the effects of GLP-1 with other treatments, such as with an analogue of the hormone amylin, to improve outcomes in type 2 diabetes. Regarding the overall ...

Shares of Eli Lilly LLY soared 14.3% on April 17 after data from a late-stage study showed that orforglipron achieved the ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Viking Therapeutics, Inc. ("Viking") , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial ...